Hospitals are seeing a shift in the causes of hemolytic disease of the fetus and newborn (HDFN), with minor blood group incompatibilities such as anti-c antibodies emerging as important culprits even when there is no ABO or Rh(D) mismatch, as illustrated by a case report published recently in the Global Journal for Research Analysis.
This case highlights the risk for newborns when these less common blood group antibodies cross the placenta and destroy fetal red blood cells, leading to severe jaundice and anemia. For patients, this means that even with modern prevention for Rh(D) disease, doctors must remain vigilant for other blood group issues to keep babies safe.
“To mitigate preventable neonatal morbidity and mortality, comprehensive red cell antigen phenotyping and extended antibody screening should be prioritized in antenatal care, particularly for women with a history of chronic transfusions,” explained the study’s authors. “Early identification enables closer fetal monitoring, timely interventions, and optimized neonatal outcomes in high-risk pregnancies complicated by alloimmunization.”
A full-term baby boy developed severe jaundice within hours of birth despite having no ABO or Rh(D) incompatibility with his mother. The mother, who had sickle cell disease, had received multiple blood transfusions before and during pregnancy, increasing the risk of developing anti-c antibodies. At just 10 hours old, the newborn’s bilirubin was already 10.8 mg/dL, prompting intensive phototherapy in the neonatal intensive care unit.
Read more about HDFN testing and diagnosis
As the baby’s condition worsened, his bilirubin climbed to 19.5 mg/dL at 16 hours of life, and his hemoglobin dropped, showing active red blood cell destruction. Doctors performed an emergency double volume exchange transfusion to replace his blood and remove antibodies. Despite this, bilirubin remained high, requiring a second exchange transfusion at 72 hours. Further testing confirmed the mother’s anti-c antibodies were responsible for the hemolytic disease.
Unlike ABO incompatibility, Rh-mediated HDFN, especially from minor antigens such as c, can be more severe and worsen with each sensitized pregnancy. Anti-c is the second most common cause of Rh-related HDFN after anti-D and can lead to life-threatening complications if unrecognized. Other Rh antigens such as C, E and e may also trigger similar reactions, though less often.
This case underscores the importance of thorough antenatal screening, particularly for mothers with conditions such as sickle cell disease who often need multiple transfusions. For these patients, extended blood group typing and antibody screening can help detect hidden risks. Identifying these incompatibilities early allows doctors to plan interventions, reducing the need for emergency treatments after birth.
Patients and families should know that while prevention with anti-D immunoglobulin has greatly reduced Rh(D) disease, other blood group mismatches still pose a threat. By working closely with their healthcare team, mothers with higher transfusion needs can help ensure the best outcomes for their babies through timely testing and careful monitoring.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
